Terns Pharmaceuticals Inc

Explore Terns Pharmaceuticals, a Nasdaq biopharma leader targeting liver disease and cancer, its volatile stock, growth, and innovative therapies.

Merck’s $6.7 billion acquisition of Terns Pharmaceuticals boosts its oncology portfolio with a promising oral CML drug, offering shareholders a premium and accelerating drug development.

Explore Terns Pharmaceuticals, a Nasdaq‑listed biopharma focused on liver‑disease and cancer drugs, its volatile stock, financial outlook, and future potential.

Explore Terns Pharmaceuticals’ latest moves in liver‑cancer drug development and market trends, plus key 2026 conference insights and investor outlook.

Explore Terns Pharmaceuticals’ latest employee inducements, market volatility and financial metrics as the biopharma firm pursues breakthroughs in liver disease and cancer.

Discover how Terns Pharmaceuticals’ 630% stock surge reflects its CML drug breakthrough, employee grants, and oncology growth strategy.

Discover how Terns Pharmaceuticals’ recent Nasdaq public offering fuels its liver‑cancer drug pipeline, boosting capital for global growth and innovation.

Discover how Terns Pharmaceuticals is pioneering oral, targeted liver‑disease and cancer drugs, driving global biotech innovation and improving patient outcomes.

Discover why Terns Pharmaceuticals’ latest CARDINAL trial data, analyst upgrades, and strong pipeline are driving a surge in investor confidence and share price.

Terns Pharmaceuticals Inc. is navigating market fluctuations with a strategic focus on liver disease and cancer treatments, positioning itself for long-term growth despite current financial challenges.